Sanofi
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNY | SANOFI.NS | PFE | BIIB | 0QYQ.IL | GLAXO.BO | |
|---|---|---|---|---|---|---|
| Market cap | 113.74B | 77.75B | 175.50B | 37.61B | 217.96B | 423.63B |
| P/E (TTM) | 23.6 | 21.3 | 44.0 | 110.2 | 40.2 | 44.4 |
| Forward P/E | 8.9 | 19.0 | 10.6 | 15.6 | — | 36.9 |
| Price/book | 1.4 | 9.4 | 2.1 | 2.0 | 10.3 | 24.8 |
| Dividend yield | 5.10% | 3.56% | 5.59% | — | 3.81% | 1.75% |
| 1-year change | −4.08% | −27.30% | +23.90% | +62.35% | +40.64% | +6.17% |
| Today | +4.72% | −2.17% | +2.63% | +2.22% | +1.70% | −1.26% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All SNY news ›Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Sanofi (OtherSNYNF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioNTech SE (BNTX) and Sanofi (SNYNF). In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioNTech SE, with a price target of…
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
Shares of Nurix Therapeutics (NRIX) slumped 38% on Wednesday, clocking its worst day ever, after Sanofi said it was ending development of the experimental oral drug SAR448272 that it licensed from Nurix, prompting Wells Fargo to lower its…
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
Nurix Therapeutics shares fell more than 30% after market close on Tuesday after the biotech disclosed that Sanofi was discontinuing development of a STAT6 degrader licensed from Nurix—but analysts don’t see the move as a critique of the…
Sanofi stops development of Nurix-partnered immune drug
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6. Many proteins still remain beyond the reach of traditional drugmaking…
Sanofi Decides to Stop Studies of Nurix-Partnered Experimental Drug
www.tokenpost.com Nurix Therapeutics said Tuesday that its partner Sanofi had decided to stop studies of an experimental inflammatory disease therapy. NRIX shares entered Wednesday’s premarket session with losses from after the mark
Nurix falls as Sanofi scraps inflammatory disease drug
Nurix Therapeutics (NRIX) stock falls as Sanofi (SNY) ends its inflammatory disease drug program. Read more here. - Nurix Therapeutics (NRIX) extended post-market losses into premarket trading on Wednesday after announcing that its partner…
Sanofi India Dividend Rs 75: Record Date and Yield
One-on-one mutual fund advisory Interim dividend Rs 75 per share (face value Rs 10). Price about Rs 3,395, yield about 2.2% on this payout. Reported record date 5 Nov 2026; verify on NSE or BSE. Sanofi India dividend news: the company has…
Nurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug
Nurix Therapeutics, Inc. (NRIX) lost roughly a third of its market value in extended trading Tuesday after Sanofi said it is walking away from an experimental oral drug licensed from the clinical-stage biotech. The Paris-based…
Nurix says Sanofi discontinues autoimmune disease drug program
Nov 3 (Reuters) – Nurix Therapeutics said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com30
- seekingalpha.com16
- markets.businessinsider.com8
- theglobeandmail.com4
- finance.biggo.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.